Best Step-Up Treatment for COPD vs Asthma and Latest Advances in Medications
For COPD, the optimal step-up treatment is a LABA/LAMA combination which provides superior exacerbation reduction compared to either LABA/ICS or monotherapy, while for asthma, adding a LAMA to LABA/ICS therapy is the most effective step-up approach for patients with uncontrolled symptoms. 1, 2
COPD Step-Up Treatment Algorithm
Initial Therapy
- Start with a single long-acting bronchodilator (LAMA preferred over LABA)
- LAMAs have greater effect on exacerbation reduction compared to LABAs (Evidence A) 1
- Tiotropium (LAMA) improves effectiveness of pulmonary rehabilitation in increasing exercise performance (Evidence B) 1
Step-Up Options Based on Symptom Persistence and Exacerbation History
For persistent symptoms with low exacerbation risk:
For frequent exacerbations with high blood eosinophil counts:
- Consider LABA/ICS or triple therapy (LABA/LAMA/ICS)
- Note: ICS use carries higher risk of pneumonia, especially in patients who smoke, are ≥55 years old, have history of exacerbations/pneumonia, or have BMI <25 kg/m² 1
For frequent exacerbations despite LABA/LAMA:
Key Advantages of LABA/LAMA for COPD
- LABA/LAMA combination decreases exacerbations to a greater extent than ICS/LABA combination 1
- Avoids pneumonia risk associated with ICS therapy 1
- Provides superior bronchodilation and symptom control 1, 3
Asthma Step-Up Treatment Algorithm
Initial Therapy
- LABA/ICS combination is the mainstay of treatment for persistent asthma
Step-Up Options
For uncontrolled symptoms despite LABA/ICS:
- Add tiotropium (LAMA) as triple therapy
- Tiotropium add-on reduces exacerbations requiring oral corticosteroids (OR 0.76,95% CI 0.57 to 1.02) 2
- Provides high-quality evidence of benefits to lung function (trough FEV1 and FVC) 2
- Shows small benefits to asthma control with fewer non-serious adverse events 2
For severe asthma with specific phenotypes:
- Consider biologics based on inflammatory markers and phenotype
Latest Advances in Medications
For COPD
Dual-pharmacology molecules:
- Muscarinic antagonist-beta2 agonist (MABA) molecules combining both actions in a single molecule 4
Novel LAMAs:
Fixed-dose LABA/LAMA combinations:
For Asthma
- Triple therapy:
Clinical Considerations and Pitfalls
COPD Treatment Pitfalls
- ICS overuse: Real-world data suggest clinicians frequently prescribe ICS when not indicated 3
- Pneumonia risk: ICS use increases pneumonia risk in COPD patients 1
- Inhaler technique: Poor inhaler technique significantly impacts symptom control; education using "teach-back" approach improves outcomes 1
Asthma Treatment Pitfalls
- LAMA monotherapy: Using a LABA without an inhaled corticosteroid is contraindicated in asthma 7
- Inadequate assessment: Failure to recognize asthma-COPD overlap can lead to suboptimal therapy 1
Device Selection Considerations
- Match device to patient's ability and preferences
- Provide proper technique education at first prescription and check periodically 1
- During acute exacerbations, nebulizers may be easier for breathless patients 1
By following these evidence-based step-up approaches and considering the latest medication advances, clinicians can optimize treatment outcomes for both COPD and asthma patients while minimizing adverse effects.